A Prospective Study to Evaluate Clinical Outcomes in Anti-LGI1 Encephalitis

Anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis has been increasingly identified as the second most common type of autoimmune encephalitis after anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. It presents with acute or subacute onset of epileptic seizures, anterograde amnesia, behavior disturbances, sleep disorders and hyponatremia. In most patients with anti-LGI1 encephalitis, immunotherapy is successful in treating the encephalitis. However, relapses, chronic epilepsy, cognitive declines and psychiatric problems have been reported in some cases. So far, prospective studies to evaluate its clinical outcomes still remain limited. In this project, the investigators will use clinical features and advanced paraclinical examinations to prospectively investigate the clinical outcomes and the associated factors in patients with anti-LGI1 encephalitis.

NCT Number	NCT06173076
Lead Sponsor	Shen Chun-Hong
Conditions	Autoimmune Encephalitis, Leucine-Rich Glioma Inactivated 1 Autoimmune Encephalitis
Enrollment	60 participants
Start Date	2022-05-18
Primary Completion	2027-12-31 (estimated)
Study Completion	2032-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-08-27